Our Work
Latham & Watkins Advises Eleusis on Sale to Beckley Psytech
October 25, 2022
Healthcare & Life Sciences team represents clinical-stage company unlocking the therapeutic potential of psychedelics.
Latham & Watkins has advised Eleusis, a life science company dedicated to unlocking the full therapeutic potential of psychedelics, on the sale of the company to Beckley Psytech, a leading clinical-stage company developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. The consideration for the transaction comprises entirely of shares in Beckley Psytech.
Latham previously advised Eleusis on its de-SPAC transaction with Silver Spike.
The Latham team was led by London corporate partner Robbie McLaren and Bay Area partner Haim Zaltzman, with London associates Jon Fox, Samantha Si, Alayna Kenney, and Saavan Shah.